- Clinical Trials
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it has initiated the first phase of branding its lead drug candidate, Oncoprex™ immunogene therapy, and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.
Upon receiving feedback from the USAN Council, which is expected later this year, Genprex will submit its non-proprietary drug name selections to the World Health Organization for International Nonproprietary Names (INN) status….
Today’s cancer treatment options are not one-size-fits-all. But Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based on a unique proprietary technology platform, is working on developing its initial drug candidate for NSCLC that would potentially benefit a large patient population who cannot currently benefit from approved therapies….
AUSTIN, Texas & CAMBRIDGE, Mass.— (July 1, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
In July 2018, the company entered a Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to fund a research study entitled, “A Novel Therapeutic Approach for the Treatment of Cancer Using a Combination of the Multifactorial Tumor Suppressor Gene TUSC2 and Immunotherapy.” The TUSC2 gene is the active agent in Genprex’s Oncoprex immunogene therapy….